

Patent  
Atty. Docket 258/235



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE #

In re the Application of: ) Group Art Unit: 1635  
Jean-Pierre Perreault, et al. ) Examiner:  
Serial No.: 09/699,667 )  
Filed: October 30, 2000 )  
For: NUCLEIC ACID ENZYME FOR RNA )  
CLEAVAGE )

4/K.T.  
5/1/01  
I.D.S.

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
Washington, D.C. 20231

Sir:

In accordance with 37 CFR §§ 1.97 and 1.98, the items identified in this Information Disclosure Statement ("IDS") are brought to the attention of the Office. The items are listed on the attached form PTO-1449 and copies are enclosed for the convenience of the Examiner.

The items identified in this IDS may or may not be "material" pursuant to 37 CFR § 1.56. The submission thereof by Applicant is not to be construed as an admission that any such patent, publication or other information referred to therein is material or considered to be material (37 CFR § 1.97(h)), or even qualifies as "prior art" under 35 USC § 102 with respect to this invention unless specifically designated by Applicant as such.

INFORMATION DISCLOSURE STATEMENT FILING PROVISION:

This IDS is believed to be timely in that it is being submitted under 37 CFR § 1.97(b), that is (1) within three months of the filing date of the application, which is not a continued prosecution application filed under § 1.53(d); or (2) within three months of entry of the national stage as set forth in 37 CFR §

CERTIFICATE OF MAILING  
(37 C.F.R. §1.8a)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as First Class Mail in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231.

April 20, 2001  
Date of Deposit

LA-190122.2

Felicia Reyes  
Name of Person Mailing Paper  
*Felicia Reyes*  
Signature of Person Mailing Paper

Patent  
Atty. Docket 258/235

1.491; or (3) before the mailing of a first Office action on the merits; or (4) before the mailing of a first Office action after filing a request for continued examination under § 1.114. Thus, no fee is required.


- However, if the undersigned is in error in this regard, Applicant respectfully requests that the Office consider this IDS as filed under 37 CFR § 1.97(c), if applicable, and charge the fee due under 37 CFR §1.17(p) to the deposit account referenced below.

**PAYMENT AND/OR AUTHORIZATION TO CHARGE FEES:**

- The Commissioner is authorized to charge any fees required by the filing of these papers, and to credit any overpayment to Lyon & Lyon's Deposit Account No. **12-2475**.

Respectfully submitted,  
LYON & LYON LLP

Dated: April 20, 2001

By: 

Lois M. Kwasigroch  
Reg. No. 35,579



22249

LYON & LYON LLP  
633 W. Fifth Street,  
Suite 4700  
Los Angeles, CA  
90071



## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

APR 23 2001

Docket Number (Optional)

258/235U

Application Number

09/699,667

Applicant(s)

Jean-Pierre Perreault et al.

Filing Date

October 30, 2000

Group Art Unit

\*EXAMINER  
INITIALS

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

9.	Andrea D. Branch and Hugh D. Robertson (1991) Efficient trans cleavage and a common structural motif for the ribozymes of the human 5' agent. Proc. Natl. Acad. Sci. USA. 88:10163-10167;
10.	Anne T. Perrotta and Michael D. Been. (1991) A pseudoknot-like structure required for efficient self-cleavage of hepatitis delta virus RNA. Nature. 350: 434-436;
11.	Adrian R. Ferré-D'Amaré, Kaihong Zhou and Jennifer A. Doudna. (1998) Crystal Structure of a hepatitis delta virus ribozyme. Nature. 395: 567-574;
12.	Jean-Pierre Perrault, Taifeng Wu, Benoit Cousineau, Kevin K. Ogilvie and Robert Cedergren (1990) Mixed deoxyribo- and ribo-ligonucleotides with catalytic activity. Nature. 344: 565-567;
13.	Michael D. Been and Gene S. Wickham (1997) Self-cleaving ribozymes of hepatitis delta virus RNA. Eur. J. Biochem. 247: 741-753;
14.	Guylaine Roy, Sirinart Ananvoranich and Jean-Pierre Perreault, (1999) Delta ribozyme has the ability to cleave <i>in trans</i> an mRNA, Nucl. Acid Res. 27:942-948;
15.	Sirinart Ananvoranich, Daniel A. Lafontaine and Jean-Pierre Perreault (1999) Mutational analysis of the antigenomic <i>trans</i> -acting delta ribozyme: the alterations of the middle nucleotides located on the P1 stem Nucl. Acid Res. 27: 1473-1479;
16.	Wolfgang A. Pieken, David B. Olsen, Fritz Benseler, Helle Aurup, Fritz Eckstein (1991) Kinetic Characterization of Ribonuclease-Resistant 2'-Modified Hammerhead Ribozymes, Science, 253: 314-317;
17.	Bharat M. Chowrira, Alfredo Berzal-Herranz, Charles F. Keller and John M. Burke (1993) Four Ribose 2'-Hydroxyl Groups Essential for Catalytic Function of the Hairpin Ribozyme, J. Biol. Chem. 268: 19458-19462;
18.	Orna Elroy-Stein and Bernard Moss (1990) Cytoplasmic expression system based on constitutive synthesis of bacteriophage T7 RNA polymerase in mammalian cells Proc. Natl. Acad. Sci. USA 87: 6743-6747;
19.	Xiang Gao and Leaf Huang (1993) Cytoplasmic expression of a reporter gene by co-delivery of T7 RNA polymerase and T7 promoter sequence with cationic liposomes Nucl. Acid Res. 21: 2867-2872;
20.	Joshua O. Ojwang, Arnold Hampel, David J. Looney, Flossie Wong-Staal and Jay Rappaport, (1992) Inhibition of human immunodeficiency virus type 1 expression by a hairpin ribozyme Proc. Natl. Acad. Sci USA 89: 10802-10806;

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**INFORMATION DISCLOSURE CITATION**  
*(Use several sheets if necessary)*

Docket Number (Optional)

258/235US

Application Number

09/699,667

Applicant(s)  
**Jean-Pierre Perreault et al.**

Filing Date

October 30, 2000

Group Art Unit

\*EXAMINER  
 INITIAL

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

21.		Shinji Makino, Ming-Fu Chang, Chien-Kou Shieh, Toshio Kamahora, David M. Vannier, Sugantha Govindarajan, Michael M. C. Cai (1987) Molecular cloning and sequencing of a human hepatitis delta (δ) virus RNA, <i>Nature</i> 329: 343-346;
22.		Jean-Pierre Perreault and Sydney Altman (1992) Important 2'-hydroxyl Groups in Model Substrates for M1 RNA, the Catalytic RNA Subunit of RNase P from <i>Escherichia coli</i> , <i>J. Mol. Biol.</i> 226: 399-409;
23.		Sirinart Ananvoranich and Jean-Pierre Perreault (1998) Substrate Specificity of δ Ribozyme Cleavage, <i>J. Biol. Chem.</i> 273: 13182-13188;
24.		Thomas W. Traut, (1994) Physiological concentrations of purines and pyrimidines. <i>Mol. Coll. Biochem.</i> 140: 1-22;
25..		Fabien Côté and Jean-Pierre Perreault (1997) Peach Latent Mosaic Viroid is locked by a 2',5'-Phosphodiester Bond Produced by <i>In Vitro</i> Self-ligation, <i>J. Mol. Biol.</i> 273: 533-543;
26..		Daniel Lafontaine, Stéphane Mercure and Jean-Pierre Perreault (1997) Update of the viroid and viroid-like sequence database: addition of a hepatitis delta virus RNA section, <i>Nucl. Acid Res.</i> 25: 123-125;
27..		Mei Chao, Sen-Yung Hsieh and John Taylor (1990) Role of Two Forms of Hepatitis Delta Virus Antigen: Evidence for a Mechanism of Self-Limiting Genome Replication, <i>J. Virol.</i> 64: 5066-5069;
28.		Stéphane Mercure, Daniel Lafontaine, Sirinart Ananvoranich and Jean-Pierre Perreault (1998) Kinetic Analysis of δ Ribozyme Cleavage, <i>Biochemistry</i> 37: 16975-16982;
29.		Hamid Fauzi, Junji Kawakami, Fumiko Nishikawa and Satoshi Nishikaw (1997) Analysis of the cleavage reaction of a trans-acting human hepatitis delta virus ribozyme, <i>Nucl. Acid Res.</i> 25: 3124-3130.
30.		M. Kashani-Sabet et al. (1992) Reversal of the Malignant Phenotype by an Anti-ras Ribozyme. <i>Antisense Research and Development</i> 2:3-15.

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.